Jefferies analyst Andrew Tsai initiated coverage of Biogen (BIIB) with a Buy rating and $190 price target The firm believes investor expectations are low with Biogen’s key risks generally understood. The shares can “grind higher” on any positive developments in 2026, including a Leqembi sales acceleration in Alzheimer’s, resiliency of the base business and late-stage pipeline success, the analyst tells investors in a research note. Jefferies sees a favorable risk/reward for Biogen at current levels, saying the stock is trading close to “no-pipeline” value.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIIB:
- Biogen’s Growth Potential Driven by Leqembi Sales and Diversified Pipeline
- Biogen, Eisai announces TGA of Australia approved LEQEMBI
- Biogen complete response letter manageable, says Citi
- Biogen’s Growth Outlook: Navigating FDA Delays and Pipeline Maturation
- Biogen’s Hold Rating Maintained Amid Uncertainty Over FDA’s CRL on Nusinersen